Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Terminated 5No longer available 2Withdrawn 1Recruiting 1Approved for marketing 1

Sponsor Class

OTHER 5INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 3Plasma cell 1Gynecologic 1

Conditions

Glioma 2Multiple Myeloma 1Glioblastoma 1Endometrial Cancer Recurrent 1Diffuse Intrinsic Pontine Glioma 1

Interventions

pembrolizumab 183Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 53fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 39Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × TIC10 compound × Clear all
NCT03295396 2025-07-28

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Jazz Pharmaceuticals

Phase 2 Terminated
73 enrolled 13 charts 1 FDA
CNS

Glioma

NCT03416530 2025-02-14

ONC201 in Pediatric H3 K27M Gliomas

Jazz Pharmaceuticals

Phase 1 Terminated
134 enrolled 1 FDA
CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT02525692 2024-12-24

Oral ONC201 in Adult Recurrent Glioblastoma

Jazz Pharmaceuticals

Phase 2 Terminated
84 enrolled 14 charts 1 FDA
CNS

Glioblastoma

NCT03485729 2024-12-24

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Jazz Pharmaceuticals

Phase 2 Terminated
27 enrolled 11 charts
Gynecologic

Endometrial Cancer Recurrent

NCT02863991 2024-07-03

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Jazz Pharmaceuticals

Phase 1/2 Terminated
17 enrolled 10 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡